Shu-Sen Wang (Shusen Wang)

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 40

Top Venues

NPJ breast cancer

Cancer medicine

International journal of cancer

Nature medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Qiao Li, Ying Cheng, Zhongsheng Tong, Yunjiang Liu, Xian Wang, Min Yan, Jianhua Chang, Shu-Sen Wang, Caiwen Du, Liang Li, Chunjiao Wu, Mingxia Wang, Zhuo Wang, Zhuli Wu, Xingli Wang, Yongli Jin, Lei Diao, Yi Sun, Yongjiao Zhang, Ai-Min Hui, Binghe Xu
HER2-targeting antibody drug conjugate FS-1502 in HER2-expressing metastatic breast cancer: a phase 1a/1b trial. Nature communications 15 (1) (2024)
Zefei Jiang, Quchang Ouyang, Tao Sun, Qingyuan Zhang, Yuee Teng, Jiuwei Cui, Hai-Bo Wang, Yongmei Yin, Xiao-Jia Wang, Xin Zhou, Yongsheng Wang, Gang Sun, Jingfen Wang, Lili Zhang, Jin Yang, Jun Qian, Min Yan, Xinlan Liu, Tienan Yi, Ying Cheng, Man Li, Aimin Zang, Shu-Sen Wang, Chuan Wang, Xinhong Wu, Jing Cheng, Hui Li, Ying Lin, Cuizhi Geng, Kangsheng Gu, Chunwei Xie, Huihua Xiong, Xiaohong Wu, Junlan Yang, Qingshan Li, Yi-Ding Chen, Fanfan Li, Anqin Zhang, Yongqiang Zhang, Yudong Wu, Jianyun Nie, Qiang Liu, Kun Wang, Xueli Mo, Lilin Chen, Yue-Yin Pan, Peifen Fu, Helong Zhang, Danmei Pang, Yuan Sheng, Yunwei Han, Hongxia Wang, Shundong Cang, Xianming Luo, Wenbo Yu, Rong Deng, Chaoqiang Yang, Patricia Keegan
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial. Nature medicine 30 (1) (2024)
Dongshao Chen, Fei Xu, Yongkui Lu, Wen Xia, Caiwen Du, Dun Xiong, Dong Song, Yanxia Shi, Zhongyu Yuan, Qiufan Zheng, Kuikui Jiang, Xin An, Cong Xue, Jiajia Huang, Xiwen Bi, Meiting Chen, Jingmin Zhang, Shu-Sen Wang, Ruoxi Hong
Pyrotinib and trastuzumab plus palbociclib and fulvestrant in HR+/HER2+ breast cancer patients with brain metastasis. NPJ breast cancer 10 (1) (2024)
Aditya Bardia, Komal L Jhaveri, Seock-Ah Im, Sonia Pernas, Michelino De Laurentiis, Shu-Sen Wang, Noelia Martínez Jañez, Giuliano Borges, David W Cescon, Masaya Hattori, Yen-Shen Lu, Erika Paige Hamilton, Qingyuan Zhang, Junji Tsurutani, Kevin M Kalinsky, Pedro Emanuel Rubini Liedke, Lu Xu, Rick M Fairhurst, Sabrina Khan, Neelima Denduluri, Hope S Rugo, Binghe Xu, Barbara Pistilli, null null
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Dongshao Chen, Fei Xu, Yongkui Lu, Wen Xia, Caiwen Du, Dun Xiong, Dong Song, Yanxia Shi, Zhongyu Yuan, Qiufan Zheng, Kuikui Jiang, Xin An, Cong Xue, Jiajia Huang, Xiwen Bi, Meiting Chen, Jingmin Zhang, Shu-Sen Wang, Ruoxi Hong
Pyrotinib and trastuzumab plus palbociclib and fulvestrant in HR+/HER2+ breast cancer patients with brain metastasis. NPJ breast cancer 10 (1) (2024)
Zefei Jiang, Quchang Ouyang, Tao Sun, Qingyuan Zhang, Yuee Teng, Jiuwei Cui, Hai-Bo Wang, Yongmei Yin, Xiao-Jia Wang, Xin Zhou, Yongsheng Wang, Gang Sun, Jingfen Wang, Lili Zhang, Jin Yang, Jun Qian, Min Yan, Xinlan Liu, Tienan Yi, Ying Cheng, Man Li, Aimin Zang, Shu-Sen Wang, Chuan Wang, Xinhong Wu, Jing Cheng, Hui Li, Ying Lin, Cuizhi Geng, Kangsheng Gu, Chunwei Xie, Huihua Xiong, Xiaohong Wu, Junlan Yang, Qingshan Li, Yi-Ding Chen, Fanfan Li, Anqin Zhang, Yongqiang Zhang, Yudong Wu, Jianyun Nie, Qiang Liu, Kun Wang, Xueli Mo, Lilin Chen, Yue-Yin Pan, Peifen Fu, Helong Zhang, Danmei Pang, Yuan Sheng, Yunwei Han, Hongxia Wang, Shundong Cang, Xianming Luo, Wenbo Yu, Rong Deng, Chaoqiang Yang, Patricia Keegan
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial. Nature medicine 30 (1) (2024)
Zefei Jiang, Quchang Ouyang, Tao Sun, Qingyuan Zhang, Yuee Teng, Jiuwei Cui, Hai-Bo Wang, Yongmei Yin, Xiao-Jia Wang, Xin Zhou, Yongsheng Wang, Gang Sun, Jingfen Wang, Lili Zhang, Jin Yang, Jun Qian, Min Yan, Xinlan Liu, Tienan Yi, Ying Cheng, Man Li, Aimin Zang, Shu-Sen Wang, Chuan Wang, Xinhong Wu, Jing Cheng, Hui Li, Ying Lin, Cuizhi Geng, Kangsheng Gu, Chunwei Xie, Huihua Xiong, Xiaohong Wu, Junlan Yang, Qingshan Li, Yi-Ding Chen, Fanfan Li, Anqin Zhang, Yongqiang Zhang, Yudong Wu, Jianyun Nie, Qiang Liu, Kun Wang, Xueli Mo, Lilin Chen, Yue-Yin Pan, Peifen Fu, Helong Zhang, Danmei Pang, Yuan Sheng, Yunwei Han, Hongxia Wang, Shundong Cang, Xianming Luo, Wenbo Yu, Rong Deng, Chaoqiang Yang, Patricia Keegan
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial. Nature medicine 30 (1) (2024)
Zefei Jiang, Quchang Ouyang, Tao Sun, Qingyuan Zhang, Yuee Teng, Jiuwei Cui, Hai-Bo Wang, Yongmei Yin, Xiao-Jia Wang, Xin Zhou, Yongsheng Wang, Gang Sun, Jingfen Wang, Lili Zhang, Jin Yang, Jun Qian, Min Yan, Xinlan Liu, Tienan Yi, Ying Cheng, Man Li, Aimin Zang, Shu-Sen Wang, Chuan Wang, Xinhong Wu, Jing Cheng, Hui Li, Ying Lin, Cuizhi Geng, Kangsheng Gu, Chunwei Xie, Huihua Xiong, Xiaohong Wu, Junlan Yang, Qingshan Li, Yi-Ding Chen, Fanfan Li, Anqin Zhang, Yongqiang Zhang, Yudong Wu, Jianyun Nie, Qiang Liu, Kun Wang, Xueli Mo, Lilin Chen, Yue-Yin Pan, Peifen Fu, Helong Zhang, Danmei Pang, Yuan Sheng, Yunwei Han, Hongxia Wang, Shundong Cang, Xianming Luo, Wenbo Yu, Rong Deng, Chaoqiang Yang, Patricia Keegan
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial. Nature medicine 30 (1) (2024)
Qiao Li, Ying Cheng, Zhongsheng Tong, Yunjiang Liu, Xian Wang, Min Yan, Jianhua Chang, Shu-Sen Wang, Caiwen Du, Liang Li, Chunjiao Wu, Mingxia Wang, Zhuo Wang, Zhuli Wu, Xingli Wang, Yongli Jin, Lei Diao, Yi Sun, Yongjiao Zhang, Ai-Min Hui, Binghe Xu
HER2-targeting antibody drug conjugate FS-1502 in HER2-expressing metastatic breast cancer: a phase 1a/1b trial. Nature communications 15 (1) (2024)
Zefei Jiang, Quchang Ouyang, Tao Sun, Qingyuan Zhang, Yuee Teng, Jiuwei Cui, Hai-Bo Wang, Yongmei Yin, Xiao-Jia Wang, Xin Zhou, Yongsheng Wang, Gang Sun, Jingfen Wang, Lili Zhang, Jin Yang, Jun Qian, Min Yan, Xinlan Liu, Tienan Yi, Ying Cheng, Man Li, Aimin Zang, Shu-Sen Wang, Chuan Wang, Xinhong Wu, Jing Cheng, Hui Li, Ying Lin, Cuizhi Geng, Kangsheng Gu, Chunwei Xie, Huihua Xiong, Xiaohong Wu, Junlan Yang, Qingshan Li, Yi-Ding Chen, Fanfan Li, Anqin Zhang, Yongqiang Zhang, Yudong Wu, Jianyun Nie, Qiang Liu, Kun Wang, Xueli Mo, Lilin Chen, Yue-Yin Pan, Peifen Fu, Helong Zhang, Danmei Pang, Yuan Sheng, Yunwei Han, Hongxia Wang, Shundong Cang, Xianming Luo, Wenbo Yu, Rong Deng, Chaoqiang Yang, Patricia Keegan
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial. Nature medicine (2024)
Zefei Jiang, Quchang Ouyang, Tao Sun, Qingyuan Zhang, Yuee Teng, Jiuwei Cui, Hai-Bo Wang, Yongmei Yin, Xiao-Jia Wang, Xin Zhou, Yongsheng Wang, Gang Sun, Jingfen Wang, Lili Zhang, Jin Yang, Jun Qian, Min Yan, Xinlan Liu, Tienan Yi, Ying Cheng, Man Li, Aimin Zang, Shu-Sen Wang, Chuan Wang, Xinhong Wu, Jing Cheng, Hui Li, Ying Lin, Cuizhi Geng, Kangsheng Gu, Chunwei Xie, Huihua Xiong, Xiaohong Wu, Junlan Yang, Qingshan Li, Yi-Ding Chen, Fanfan Li, Anqin Zhang, Yongqiang Zhang, Yudong Wu, Jianyun Nie, Qiang Liu, Kun Wang, Xueli Mo, Lilin Chen, Yue-Yin Pan, Peifen Fu, Helong Zhang, Danmei Pang, Yuan Sheng, Yunwei Han, Hongxia Wang, Shundong Cang, Xianming Luo, Wenbo Yu, Rong Deng, Chaoqiang Yang, Patricia Keegan
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial. Nature medicine 30 (1) (2024)
Qiao Li, Ying Cheng, Zhongsheng Tong, Yunjiang Liu, Xian Wang, Min Yan, Jianhua Chang, Shu-Sen Wang, Caiwen Du, Liang Li, Chunjiao Wu, Mingxia Wang, Zhuo Wang, Zhuli Wu, Xingli Wang, Yongli Jin, Lei Diao, Yi Sun, Yongjiao Zhang, Ai-Min Hui, Binghe Xu
HER2-targeting antibody drug conjugate FS-1502 in HER2-expressing metastatic breast cancer: a phase 1a/1b trial. Nature communications 15 (1) (2024)
Dongshao Chen, Fei Xu, Yongkui Lu, Wen Xia, Caiwen Du, Dun Xiong, Dong Song, Yanxia Shi, Zhongyu Yuan, Qiufan Zheng, Kuikui Jiang, Xin An, Cong Xue, Jiajia Huang, Xiwen Bi, Meiting Chen, Jingmin Zhang, Shu-Sen Wang, Ruoxi Hong
Pyrotinib and trastuzumab plus palbociclib and fulvestrant in HR+/HER2+ breast cancer patients with brain metastasis. NPJ breast cancer 10 (1) (2024)
Mengqian Ni, Fang Wang, Anli Yang, Qiong Shao, Cong Xue, Wen Xia, Fei Xu, Xi Lin, Jiajia Huang, Xiwen Bi, Ruoxi Hong, Mei-Ting Chen, Qiufan Zheng, Kuikui Jiang, Xinhua Xie, Jun Tang, Xi Wang, Zhongyu Yuan, Shu-Sen Wang, Yanxia Shi, Xin An
What is the appropriate genetic testing criteria for breast cancer in the Chinese population?-Analysis of genetic and clinical features from a single cancer center database. Cancer medicine (2023)
Liye Wang, Peng Sun, Fei Xu, Qiufan Zheng, Kui-Kui Jiang, Ruoxi Hong, Shu-Sen Wang
Construction of immune score and its prognostic value in invasive lobular carcinoma of the breast using computational pathology analysis. Cancer medicine (2023)
Liye Wang, Peng Sun, Fei Xu, Qiufan Zheng, Kui-Kui Jiang, Ruoxi Hong, Shu-Sen Wang
Construction of immune score and its prognostic value in invasive lobular carcinoma of the breast using computational pathology analysis. Cancer medicine (2023)
Mengqian Ni, Fang Wang, Anli Yang, Qiong Shao, Cong Xue, Wen Xia, Fei Xu, Xi Lin, Jiajia Huang, Xiwen Bi, Ruoxi Hong, Mei-Ting Chen, Qiufan Zheng, Kuikui Jiang, Xinhua Xie, Jun Tang, Xi Wang, Zhongyu Yuan, Shu-Sen Wang, Yanxia Shi, Xin An
What is the appropriate genetic testing criteria for breast cancer in the Chinese population?-Analysis of genetic and clinical features from a single cancer center database. Cancer medicine (2023)
Danyang Zhou, Mei Li, Mohamed Hussein Yasin, Qianyi Lu, Jia Fu, Kuikui Jiang, Ruoxi Hong, Shu-Sen Wang, Fei Xu
The prognostic value and immune microenvironment association of AR in HER2+ nonmetastatic breast cancer. NPJ breast cancer 9 (1) (2023)
Danyang Zhou, Mei Li, Mohamed Hussein Yasin, Qianyi Lu, Jia Fu, Kuikui Jiang, Ruoxi Hong, Shu-Sen Wang, Fei Xu
The prognostic value and immune microenvironment association of AR in HER2+ nonmetastatic breast cancer. NPJ breast cancer 9 (1) (2023)
Liye Wang, Peng Sun, Fei Xu, Qiufan Zheng, Kui-Kui Jiang, Ruoxi Hong, Shu-Sen Wang
Construction of immune score and its prognostic value in invasive lobular carcinoma of the breast using computational pathology analysis. Cancer medicine 13 (1) (2023)
Danyang Zhou, Mei Li, Mohamed Hussein Yasin, Qianyi Lu, Jia Fu, Kuikui Jiang, Ruoxi Hong, Shu-Sen Wang, Fei Xu
The prognostic value and immune microenvironment association of AR in HER2+ nonmetastatic breast cancer. NPJ breast cancer 9 (1) (2023)
Binghe Xu, Fei Ma, Tao Wang, Shu-Sen Wang, Zhongsheng Tong, Wei Li, Xinhong Wu, Xiaojia Wang, Tao Sun, Yueyin Pan, Herui Yao, Xian Wang, Ting Luo, Jin Yang, Xiaohua Zeng, Weihong Zhao, Xiuyu Julie Cong, Jiongjie Chen
A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments. International journal of cancer 152 (10) (2023)
Binghe Xu, Fei Ma, Tao Wang, Shu-Sen Wang, Zhongsheng Tong, Wei Li, Xinhong Wu, Xiaojia Wang, Tao Sun, Yueyin Pan, Herui Yao, Xian Wang, Ting Luo, Jin Yang, Xiaohua Zeng, Weihong Zhao, Xiuyu Julie Cong, Jiongjie Chen
A phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments. International journal of cancer (2023)
Binghe Xu, Fei Ma, Tao Wang, Shu-Sen Wang, Zhongsheng Tong, Wei Li, Xinhong Wu, Xiaojia Wang, Tao Sun, Yueyin Pan, Herui Yao, Xian Wang, Ting Luo, Jin Yang, Xiaohua Zeng, Weihong Zhao, Xiuyu Julie Cong, Jiongjie Chen
A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments. International journal of cancer (2023)
Mengqian Ni, Fang Wang, Anli Yang, Qiong Shao, Cong Xue, Wen Xia, Fei Xu, Xi Lin, Jiajia Huang, Xiwen Bi, Ruoxi Hong, Mei-Ting Chen, Qiufan Zheng, Kuikui Jiang, Xinhua Xie, Jun Tang, Xi Wang, Zhongyu Yuan, Shu-Sen Wang, Yanxia Shi, Xin An
What is the appropriate genetic testing criteria for breast cancer in the Chinese population?-Analysis of genetic and clinical features from a single cancer center database. Cancer medicine (2023)
Binghe Xu, Fei Ma, Tao Wang, Shu-Sen Wang, Zhongsheng Tong, Wei Li, Xinhong Wu, Xiaojia Wang, Tao Sun, Yueyin Pan, Herui Yao, Xian Wang, Ting Luo, Jin Yang, Xiaohua Zeng, Weihong Zhao, Xiuyu Julie Cong, Jiongjie Chen
A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments. International journal of cancer 152 (10) (2023)
Binghe Xu, Fei Ma, Tao Wang, Shu-Sen Wang, Zhongsheng Tong, Wei Li, Xinhong Wu, Xiaojia Wang, Tao Sun, Yueyin Pan, Herui Yao, Xian Wang, Ting Luo, Jin Yang, Xiaohua Zeng, Weihong Zhao, Xiuyu Julie Cong, Jiongjie Chen
A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments. International journal of cancer 152 (10) (2023)
Liye Wang, Peng Sun, Fei Xu, Qiufan Zheng, Kui-Kui Jiang, Ruoxi Hong, Shu-Sen Wang
Construction of immune score and its prognostic value in invasive lobular carcinoma of the breast using computational pathology analysis. Cancer medicine (2023)
Danyang Zhou, Mei Li, Mohamed Hussein Yasin, Qianyi Lu, Jia Fu, Kuikui Jiang, Ruoxi Hong, Shu-Sen Wang, Fei Xu
The prognostic value and immune microenvironment association of AR in HER2+ nonmetastatic breast cancer. NPJ breast cancer 9 (1) (2023)
Danyang Zhou, Mei Li, Mohamed Hussein Yasin, Qianyi Lu, Jia Fu, Kuikui Jiang, Ruoxi Hong, Shu-Sen Wang, Fei Xu
The prognostic value and immune microenvironment association of AR in HER2+ nonmetastatic breast cancer. NPJ breast cancer 9 (1) (2023)
Danyang Zhou, Mei Li, Mohamed Hussein Yasin, Qianyi Lu, Jia Fu, Kuikui Jiang, Ruoxi Hong, Shu-Sen Wang, Fei Xu
The prognostic value and immune microenvironment association of AR in HER2+ nonmetastatic breast cancer. NPJ breast cancer 9 (1) (2023)
Binghe Xu, Fei Ma, Tao Wang, Shu-Sen Wang, Zhongsheng Tong, Wei Li, Xinhong Wu, Xiaojia Wang, Tao Sun, Yueyin Pan, Herui Yao, Xian Wang, Ting Luo, Jin Yang, Xiaohua Zeng, Weihong Zhao, Xiuyu Julie Cong, Jiongjie Chen
A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments. International journal of cancer 152 (10) (2023)
Yanhong Su, Yarui Zhang, Xin Hua, Jiajia Huang, Xiwen Bi, Wen Xia, Xinyue Wang, Zhangzan Huang, Chenge Song, Yongyi Zhong, Yanxia Shi, Shu-Sen Wang, null null, Wei Fan, Zhongyu Yuan
High-dose tamoxifen in high-hormone-receptor-expressing advanced breast cancer patients: a phase II pilot study. Therapeutic advances in medical oncology 13 (2021)
Fengzhu Guo, Zongbi Yi, Wenna Wang, Yi-Qun Han, Pei Yu, Su Zhang, Quchang Ouyang, Min Yan, Xiaojia Wang, Xichun Hu, Zefei Jiang, Tao Huang, Zhongsheng Tong, Shu-Sen Wang, Yongmei Yin, Hui Li, Runxiang Yang, Huawei Yang, Yuee Teng, Tao Sun, Li Cai, Hongyuan Li, Xi Chen, Jianjun He, Xinlan Liu, Shune Yang, Jinhu Fan, You Lin Qiao, Jiayu Wang, Bing-He Xu
Profile, treatment patterns, and influencing factors of anthracycline use in breast cancer patients in China: A nation-wide multicenter study. Cancer medicine 10 (19) (2021)
Xin An, Xuefen Lei, Riqing Huang, Rongzhen Luo, Haifeng Li, Fei Xu, Zhongyu Yuan, Shu-Sen Wang, Alexandre de Nonneville, Anthony Gonçalves, Gilles Houvenaeghel, JiBin Li, Cong Xue, Yanxia Shi
Adjuvant chemotherapy for small, lymph node-negative, triple-negative breast cancer: A single-center study and a meta-analysis of the published literature. Cancer (2021)
Ruoxi Hong, Wen Xia, Liye Wang, Kaping Lee, Qianyi Lu, Kuikui Jiang, Shengfeng Li, Jinquan Yu, Jin Wei, Weijia Tang, Danyang Zhou, Xin An, Jiajia Huang, Cong Xue, Xiwen Bi, Yanxia Shi, Zhongyu Yuan, Fei Xu, Shu-Sen Wang
Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2-positive breast cancer: An open-label, dose-escalation, phase I study. Cancer communications (London, England) 41 (2) (2021)
Xin Hua, Xi-Wen Bi, Jian-Li Zhao, Yan-Xia Shi, Ying Lin, Zhi-Yong Wu, Yuan-Qi Zhang, Le-Hong Zhang, An-Qing Zhang, Heng Huang, Xin-Mei Liu, Fei Xu, Ying Guo, Wen Xia, Ruo-Xi Hong, Kui-Kui Jiang, Cong Xue, Xin An, Yong-Yi Zhong, Shu-Sen Wang, Jia-Jia Huang, Zhong-Yu Yuan
Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Metastatic Breast Cancer with Hormone Receptor-positive and HER2-positive (SYSUCC-002). Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Qianyi Lu, Kaping Lee, Fei Xu, Wen Xia, Qiufan Zheng, Ruoxi Hong, Kuikui Jiang, Qinglian Zhai, Yuan Li, Yanxia Shi, Zhongyu Yuan, Shu-Sen Wang
Metronomic chemotherapy of cyclophosphamide plus methotrexate for advanced breast cancer: Real-world data analyses and experience of one center. Cancer communications (London, England) 40 (5) (2020)
Fei Xu, Qiufan Zheng, Wen Xia, Quchang Ouyang, Danmei Pang, Zhongyu Yuan, Yanxia Shi, Roujun Peng, Qianyi Lu, Shu-Sen Wang
A Phase II Study of Fulvestrant 500 mg as Maintenance Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Patients with Advanced Breast Cancer After First-Line Chemotherapy. The oncologist 26 (5) (2020)
Zong-Bi Yi, Pei Yu, Su Zhang, Wen-Na Wang, Yi-Qun Han, Qu-Chang Ouyang, Min Yan, Xiao-Jia Wang, Xi-Chun Hu, Ze-Fei Jiang, Tao Huang, Zhong-Sheng Tong, Shu-Sen Wang, Yong-Mei Yin, Hui Li, Run-Xiang Yang, Hua-Wei Yang, Yue-E Teng, Tao Sun, Li Cai, Hong-Yuan Li, Xi Chen, Jian-Jun He, Xin-Lan Liu, Shun-E Yang, Jia-Yu Wang, Jin-Hu Fan, You-Lin Qiao, Bing-He Xu
Profile and outcome of receptor conversion in breast cancer metastases: a nation-wide multicenter epidemiological study. International journal of cancer 148 (3) (2020)

Shu-Sen Wang.css-eqlu8i{font-size:small;padding-left:4px;} (Shusen Wang)

Publication Activity (10 Years)

Top Topics

Top Venues

Shu-Sen Wang (Shusen Wang)